Edward Rico, MD
Endocrinology, Diabetes & Metabolism · Terre Haute, INNPI 1477739423
Payments from drug & device makers
Across 469 payments — averaging $287.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$84K
- AstraZeneca$20K
- Johnson & Johnson$14K
- Sanofi-aventis U.S. LLC$13K
- Lilly USA, LLC$396
- Medtronic$238
- plus $2K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 164 | $84,231 |
| AstraZeneca | 40 | $20,293 |
| Johnson & Johnson | 74 | $14,498 |
| Sanofi-aventis U.S. LLC | 32 | $12,989 |
| Lilly USA, LLC | 21 | $396 |
| Medtronic(2 entities) | 7 | $238 |
| Abbott | 16 | $214 |
| Insulet Corporation | 13 | $205 |
| Boehringer Ingelheim | 12 | $200 |
| Mannkind Corporation | 7 | $180 |
| Xeris Pharmaceuticals, Inc. | 9 | $170 |
| Amgen(2 entities) | 10 | $164 |
| AbbVie | 8 | $116 |
| Merck | 8 | $114 |
| Corcept Therapeutics | 6 | $102 |
| Antares Pharma, Inc. | 5 | $74 |
| IBSA Pharma Inc. | 4 | $72 |
| Clarus Therapeutics Inc. | 5 | $70 |
| Dexcom, Inc. | 4 | $63 |
| Recordati_rare_diseases_inc. | 4 | $63 |
| Tandem Diabetes Care, Inc. | 4 | $59 |
| Pfizer | 3 | $49 |
| Novartis | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Echosens North America, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Zealand Pharma US, Inc. | 1 | $12 |
How this compares
$134,767 in reported general payments places this provider in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Terre Haute
- Isaiah PittmanTerre Haute$1.5M
- Mohammad AlamTerre Haute$28K
- Carmella Evans-MolinaIndianapolis$6.3M
- Ernest AsamoahIndianapolis$959K
- Sana MeahMunster$829K
- James MaloneIndianapolis$822K
- Erica KretchmanRichmond$636K
- Emily VeenemanSeymour$583K
- Cary MariashIndianapolis$435K
- Marian KirkmanIndianapolis$371K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.